Biogen Inc.
BIIB NASDAQHealthcare ★★★★★Latest Earnings Above forecast↑
Date
Jul 29, 2026
ET
EPS Est.
2.94
EPS Actual
3.60
Revenue Est.
$2.46B
Revenue Actual
$2.74B
Next Earnings Report
Date
Oct 29, 2026 · Thu
Time
Pre-market
Fiscal Period
FY2026 Q3
EPS Est.
2.03
Revenue Est.
$2.64B
Company Overview
Biogen Inc. (ticker BIIB) is listed on NASDAQ with a market cap of about $32.03B. Its next earnings report (FY2026 Q3) is expected on Oct 29, 2026 (ET), Pre-market, with consensus EPS of 2.03. In the last 15 reported quarters, EPS beat consensus estimates 14 times.
Actual EPS TrendRecently15Term · Feb 15, 2023 → Jul 29, 2026
Feb 15, 2023Range: 1.99 ~ 5.47Jul 29, 2026
Earnings History
| Date | Fiscal Period | EPS Est. | EPS Actual | Revenue Est. | Revenue Actual |
|---|---|---|---|---|---|
| Jul 29, 2026 | -- | 2.94 | Above forecast↑3.60 | $2.46B | $2.74B |
| Apr 29, 2026 | -- | 3.05 | Above forecast↑3.57 | $2.29B | $2.48B |
| Feb 6, 2026 | -- | 1.63 | Above forecast↑1.99 | $2.2B | $2.28B |
| Oct 30, 2025 | -- | 3.88 | Above forecast↑4.81 | $2.34B | $2.45B |
| Jul 31, 2025 | -- | 3.90 | Above forecast↑5.47 | $2.33B | $2.65B |
| May 1, 2025 | -- | 2.90 | 3.02 | $2.23B | $2.43B |
| Feb 12, 2025 | -- | 3.43 | 3.44 | $2.41B | $2.45B |
| Oct 30, 2024 | -- | 3.77 | 4.08 | $2.43B | $2.47B |
| Aug 1, 2024 | -- | 4.07 | Above forecast↑5.28 | $2.39B | $2.35B |
| Apr 24, 2024 | -- | 3.47 | 3.67 | $2.31B | $2.29B |
| Feb 13, 2024 | -- | 3.16 | 2.95 | $2.47B | $2.39B |
| Nov 8, 2023 | -- | 3.99 | 4.36 | $2.39B | $2.53B |
| Jul 25, 2023 | -- | 3.77 | 4.02 | $2.37B | $2.46B |
| Apr 25, 2023 | -- | 3.28 | 3.40 | $2.34B | $2.46B |
| Feb 15, 2023 | -- | 3.48 | Above forecast↑4.05 | $2.45B | $2.54B |
Original Filings (SEC)
10-Q2026-07-29 ↗
8-K2026-07-29 ↗
8-K2026-07-01 ↗
8-K2026-06-10 ↗
8-K2026-05-14 ↗
10-Q2026-04-29 ↗
8-K2026-04-29 ↗
8-K2026-04-06 ↗
Links point to the company's original filings on the U.S. Securities and Exchange Commission (SEC) website.
Report dates are US trading days (Eastern Time); EPS and revenue estimates are market consensus, in USD. This page is for reference only and does not constitute investment advice.
